Cystic Fibrosis

Study Outline

The dose-escalating study aims to evaluate the safety, tolerability and efficacy of ARO-ENaC in Cystic Fibrosis patients.

To find out if this trial is suitable for you please register below or contact our Clinical Trials Team at admin@resphealth.uwa.edu.au or phone 6151 0888.

Eligibility & Requirements

Aged 18 or over with a diagnosis of cystic fibrosis
FEV1 between 40% and 90% predicted
No History of organ transplantation
Not pregnant or breastfeeding

What's Involved

You will be required to attend at least 16 visits to the Institute for Respiratory Health at the QEII Medical Centre in Nedlands.
Complete one phone call for up to approximately 16 weeks (please note, there is also up to 28 days in the screening period of the study).

Principal Investigator

Dr Siobhain Mulrennan

I have been diagnosed with:
Name*
First Last
Phone*
Email*
Address
Street Address Address Line 2 City State / Province / Region ZIP / Postal Code Country
Receive our newsletter?
- Yes
Comments
This field is for validation purposes and should be left unchanged.

Current Clinical Trials

Alpha1 Antitrypsin Deficiency

GTi1201

INS1007-301

D9180C00002

PACE

Bayesian Evidence-Adaptive Treatment in Cystic Fibrosis (BEAT CF)

Cystic Fibrosis

ARO-ENaC-1001

IPF Study

IM027-040